URGN vs. NYAX
URGN (UroGen Pharma Ltd.) and NYAX (Nayax Ltd) are both stocks. URGN operates in Biotechnology (Healthcare), while NYAX operates in Information Technology Services (Technology). Over the past 3 years, URGN returned 23.50%/yr vs 47.10%/yr for NYAX. Their 0.07 correlation means their historical movements had little consistent relationship.
Performance
URGN vs. NYAX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, URGN achieves a 63.28% return, which is significantly higher than NYAX's 34.92% return.
URGN
- 1D
- -6.94%
- 1M
- 0.58%
- 6M
- 95.00%
- YTD
- 63.28%
- 1Y
- 97.11%
- 3Y*
- 23.50%
- 5Y*
- 19.79%
- 10Y*
- —
- ALL TIME*
- 12.12%
NYAX
- 1D
- 2.46%
- 1M
- -2.78%
- 6M
- 21.66%
- YTD
- 34.92%
- 1Y
- 60.07%
- 3Y*
- 47.10%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 19.58%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
NYAX Nayax Ltd | $441.71K | $773.18K | $1.39M |
| $24.52M | $29.78M | $26.02M |
URGN vs. NYAX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
URGN UroGen Pharma Ltd. | 63.28% | 119.91% | -29.00% | 69.11% | 3.99% |
NYAX Nayax Ltd | 34.92% | 73.53% | 53.08% | -3.30% | -42.48% |
Correlation
The correlation between URGN and NYAX is 0.02, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.02 |
Correlation (3Y) Balances recent behavior with more history. | 0.06 |
Correlation (All Time) Calculated using the full available price history since Sep 21, 2022 | 0.07 |
Fundamentals
URGN:
$1.86B
NYAX:
$2.50B
URGN:
-$2.71
NYAX:
$0.76
URGN:
13.38
NYAX:
6.25
URGN:
$140.49M
NYAX:
$429.22M
URGN:
$126.24M
NYAX:
$195.18M
URGN:
-$117.04M
NYAX:
$69.76M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
URGN vs. NYAX — Risk / Return Rank
URGN
NYAX
URGN vs. NYAX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and Nayax Ltd (NYAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| URGN | NYAX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.12 | ||
| Sortino ratioReturn per unit of downside risk | +0.25 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.24 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 2.40 | 2.60 | -0.20 |
| Martin ratioReturn relative to average drawdown | 4.98 | 6.13 | -1.15 |
Loading charts...
Drawdowns
URGN vs. NYAX - Drawdown Comparison
The maximum URGN drawdown since its inception was -93.98%, which is greater than NYAX's maximum drawdown of -52.18%. Use the drawdown chart below to compare losses from any high point for URGN and NYAX.
Loading charts...
Drawdown Indicators
| URGN | NYAX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.98% | -52.18% | -41.80% |
Max Drawdown (1Y)Largest decline over 1 year | -42.22% | -22.57% | -19.65% |
Max Drawdown (3Y)Largest decline over 3 years | -82.64% | -31.25% | -51.39% |
Max Drawdown (5Y)Largest decline over 5 years | -82.64% | — | — |
Current DrawdownCurrent decline from peak | -41.47% | -9.95% | -31.52% |
Average DrawdownAverage peak-to-trough decline | -61.22% | -23.30% | -37.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.29% | 9.55% | +10.74% |
Volatility
URGN vs. NYAX - Volatility Comparison
UroGen Pharma Ltd. (URGN) and Nayax Ltd (NYAX) have volatilities of 14.36% and 13.73%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| URGN | NYAX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.36% | 13.73% | +0.63% |
Volatility (6M)Calculated over the trailing 6-month period | 41.70% | 32.25% | +9.45% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.71% | 41.52% | +24.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.70% | 51.29% | +40.41% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.11% | 51.29% | +27.82% |
Dividends
URGN vs. NYAX - Dividend Comparison
Neither URGN nor NYAX has paid dividends to shareholders.
Financials
URGN vs. NYAX - Financials Comparison
This section allows you to compare key financial metrics between UroGen Pharma Ltd. and Nayax Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
URGN vs. NYAX - Profitability Comparison
URGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, UroGen Pharma Ltd. reported a gross profit of 46.82M and revenue of 50.96M. Therefore, the gross margin over that period was 91.9%.
NYAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Nayax Ltd reported a gross profit of 48.02M and revenue of 105.91M. Therefore, the gross margin over that period was 45.3%.
URGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, UroGen Pharma Ltd. reported an operating income of -20.26M and revenue of 50.96M, resulting in an operating margin of -39.8%.
NYAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Nayax Ltd reported an operating income of 4.10M and revenue of 105.91M, resulting in an operating margin of 3.9%.
URGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, UroGen Pharma Ltd. reported a net income of -23.57M and revenue of 50.96M, resulting in a net margin of -46.3%.
NYAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Nayax Ltd reported a net income of 1.27M and revenue of 105.91M, resulting in a net margin of 1.2%.
Frequently Asked Questions
URGN and NYAX have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
URGN has higher volatility (14.36%) compared to NYAX (13.73%). In terms of maximum drawdown, URGN dropped -93.98% vs NYAX's -52.18%.
URGN currently has the higher Sharpe Ratio (1.54 vs 1.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for URGN and NYAX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer